Skip to main content

Advertisement

Table 2 Characteristics of 6 randomized trials comparing gemcitabine to gemcitabine plus fluoropyrimidine

From: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

Reference Year n Treatment regimen Stage IV (%) Male (%) PS 0–1 (%)
Berlin 2002 162 Gem 1000 mg/m2 for 3 of 4 wks 90 54 86
   160 Gem 1000 mg/m2 + 5-FU 600 mg/m2 for 3 of 4 wks 89 52 86
Riess 2005 238 Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks 77 54 48*
   235 Gem 1000 mg/m2 + FA 200 mg/m2 5-FU 750 mg/m2 CI × 4 wks q 6 wks 77 52 44*
DiCostanzo 2005 48 Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks 73 48 69
   43 Gem 1000 mg/m2 + CI 5-FU 200 mg/m2 for 6 of 7 wks, then wkly for 3 of 4 wks 67 63 67
Scheithauer 2003 42 Gem 2200 mg/m2 q 2 wks 100 55 24
   41 Gem 2200 mg/m2 + Capecitabine 2500 mg/m2 d1-7 q 2 wks 100 66 27
Herrmann 2005 159 Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks 79 53 53*
   160 Gem 1000 mg/m2 d1, 8 + Capecitabine 2 × 650 mg/m2 d1-14 q 3 wks 80 54 53*
Cunningham 2005 266 Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks 71 na 82
   267 Gem 1000 mg/m2 d1, 8, 15 + Capecitabine 2 × 830 mg/m2 d1-21 q 4 wks 70 na 81
  1. * KPS = 90–100%; PS = performance status; na = data not available;